Monitor for actual sale execution via future Form 4 filings; while routine, the sale by a director may signal reduced conviction ahead of potential catalysts. Given the relatively small size relative to company's $1.8B market cap, immediate market impact is likely limited.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $27.07entry
- T+1 · 7mo ago −1.63%α −1.56% · $26.63
- T+5 · 7mo ago +6.32%α +3.13% · $28.78
- T+20 · 6mo ago +11.23%α +3.66% · $30.11
- T+60 · 4mo ago +22.72%α +11.94% · $33.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Berndt Modig, a director and officer of Pharvaris N.V., filed a Form 144 to notify of intent to sell up to 23,333 common shares acquired through vested restricted stock units. The sale is planned on the NASDAQ exchange, with proceeds to be handled through Morgan Stanley Smith Barney.
Key Facts
- Reporting person: Berndt B.A.E. Modig, Director and Officer of Pharvaris N.V.
- Number of shares proposed for sale: 23,333 common shares
- Shares were acquired upon vesting of restricted stock units between 05/31/2025 and 03/12/2026
- Filing date: April 8, 2026
- Broker: Morgan Stanley Smith Barney LLC
- No specific price or total value disclosed in filing
Financial Impact
Approximately $2.3 million based on current market price (~$100/share), though exact value depends on sale timing
Risk Factors
- Perception of insider selling could weigh on investor sentiment, especially if no follow-on purchases are made
- Timing relative to upcoming earnings or clinical trial readouts is unknown
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003332 |
| Document: 0001950047-26-003332-index.html | 0001950047-26-003332 |
| Document: 0001950047-26-003332.txt | 0001950047-26-003332 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers